All In Biotech

Drug Trial Radar · NCT06704347

Safety Study of XT-150 in Participants With ALS

A Phase 1, Open-Label Study Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Biomarkers of Single Ascending Dose Regimens of XT-150 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

8

Planned (sponsor's estimate)

Start

Mar 2027

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Xalud Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Nov 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, multi-center safety study of XT-150 in adult participants with Amyotrophic Lateral Sclerosis (ALS). Participants providing informed consent and meeting all study eligibility criteria will be enrolled in the study and will receive a single injection of XT-150 at the Baseline visit. Follow-up visits will occur over 180 days (6 months) after the injection. 8 participants (4 participants per dose level) will be enrolled sequentially in up to 2 ascending, single dose cohorts: Cohort 1: 1.5 mg XT-150 Cohort 2: 4.5 mg XT-150

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • XT-150Biological

    XT-150 is a small piece of plasmid DNA (genetic material) that produces a variant of the anti-inflammatory cytokine, Interleukin 10 (IL-10).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants reporting adverse events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)Time frame: Up to Day 180
  2. Number of participants with clinically significant physical examination findingsTime frame: Up to Day 180
  3. Number of participants with clinically significant vital sign abnormalitiesTime frame: Up to Day 180
  4. Number of participants with clinically significant laboratory abnormalitiesTime frame: Up to Day 180

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Barrow Neurological Institute (St. Joseph's)

    Phoenix, Arizona

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Henry Ford Health

    Detroit, Michigan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.